1. Estetrol‐Drospirenone combination oral contraceptive: a clinical study of contraceptive efficacy, bleeding pattern and safety in Europe and Russia
- Author
-
Jost M, Creinin, Apolikhina I, Zatik J, Suturina L, Weyers S, Apter D, Terhi Piltonen, Kristina Gemzell-Danielsson, and Jean-Michel Foidart
- Subjects
Reproductive health and childbirth ,Medical and Health Sciences ,Russia ,Medicine and Health Sciences ,ESTRADIOL ,Acne ,Combined ,Obstetrics ,Estetrol ,contraceptive efficacy ,Obstetrics and Gynecology ,Metrorrhagia ,Contraceptives ,Hematology ,combined oral contraception ,Middle Aged ,estetrol ,Europe ,Contraceptives, Oral, Combined ,6.1 Pharmaceuticals ,PHASE-II ,Female ,Patient Safety ,medicine.symptom ,Bleeding pattern ,medicine.drug ,Oral ,safety ,Adult ,medicine.medical_specialty ,Adolescent ,Clinical Trials and Supportive Activities ,NUCLEAR ,METABOLISM ,Placebo ,Young Adult ,Clinical Research ,medicine ,Humans ,Vaginal bleeding ,CYCLE ,Obstetrics & Reproductive Medicine ,Adverse effect ,VENOUS THROMBOEMBOLISM ,business.industry ,Contraception/Reproduction ,Evaluation of treatments and therapeutic interventions ,Drospirenone ,medicine.disease ,Regimen ,native estrogen ,MEMBRANE ,business ,drospirenone ,Body mass index - Abstract
Author(s): Gemzell-Danielsson, K; Apter, D; Zatik, J; Weyers, S; Piltonen, T; Suturina, L; Apolikhina, I; Jost, M; Creinin, MD; Foidart, J-M | Abstract: ObjectivesTo assess the contraceptive efficacy, bleeding pattern and safety of a combined oral contraceptive containing estetrol (E4) 15nmg and drospirenone (DRSP) 3nmg.DesignMulticenter, open-label, phase 3 trial.SettingSixty-nine sites in Europe and Russia.PopulationSexually active women aged 18-50nyears with regular menstrual cycles and body mass index ≤35nkg/m2 .MethodsE4/DRSP was administered in a 24 active/4 placebo regimen for up to 13 cycles. Visits were scheduled during Cycles 2, 4, 7 and 10 and after completing treatment during which adverse events (AEs) were collected. Participants recorded medication intake, vaginal bleeding/spotting, use of other contraceptive methods and sexual intercourse on a daily diary.Main outcome measuresPearl Index (PI) for women 18-35nyears (overall and method-failure), bleeding pattern and AEs.ResultsA total of 1553 women aged 18-50nyears, including 1353 from 18 to 35nyears old, received the study medication. PI was 0.47 pregnancies/100 woman-years (95% CI 0.15-1.11); method failure PI was 0.29 pregnancies/100 woman-years (95% CI 0.06-0.83). Scheduled bleeding/spotting occurred in 91.9-94.4% of women over Cycles 1 to 12 and lasted a median of 4-5ndays per cycle. The percentage of women with unscheduled bleeding/spotting episodes decreased from 23.5% in Cycle 1 to l16% from Cycle 6 onwards. The most common AEs were headache (7.7%), metrorrhagia (5.5%), vaginal haemorrhage (4.8%) and acne (4.2%). One treatment-related serious AE was reported, a lower extremity venous thromboembolism. One-hundred and forty-one (9.1%) women discontinued study participation because of treatment-related adverse events.ConclusionE4/DRSP provides effective contraception, a predictable bleeding pattern and a favourable safety profile.Tweetable abstractA phase 3 trial with E4/DRSP shows high contraceptive efficacy, a predictable bleeding pattern and favourable safety profile.
- Published
- 2021
- Full Text
- View/download PDF